Fig. 6: Oral administration of ASP4132 inhibits NSCLC xenograft growth in SCID mice.
From: AMPK activation by ASP4132 inhibits non-small cell lung cancer cell growth
The SCID mice-bearing pNSCLC-1 xenograft tumors were treated with ASP4132 (oral administration, 5 mg/kg body weight, daily for 21 days) or vehicle control (ten mice per group/n = 10); Estimated tumor volumes (A) and mice body weights (D) were recorded every six days for a total of 42 days; Estimated daily tumor growth was calculated using the described formula (B); At the end of experiments, Day-42, tumors of the two groups were separated via surgery and weighted individually (C). At experimental Day-7 and Day-14, 4 h after ASP4132/vehicle administration, one tumor of each group was isolated and tumor tissues were subjected to Western blotting assay of listed proteins (E–H). Expression of listed proteins was quantified (E–H). Data were presented as mean ± standard deviation (SD).
